---
title: "Zymeworks: Its Post-Approval Future"
date: "2025-02-10 18:53:18"
summary: "Bill Oxford  Shares of solid tumor concern Zymeworks Inc. (NASDAQ:ZYME) have barely budged since the company obtained its first approval via an out-licensing deal for its bispecific HER2 antibody Ziihera. Global rights (ex-Asia) holder Jazz Pharmaceuticals (JAZZ) believes"
categories:
  - "seekalpha_articles"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha_articles"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/184964962/image_184964962.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

![Biotech Investing](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/184964962/image_184964962.jpg?io=getty-c-w750) 



Bill Oxford





Shares of solid tumor concern **Zymeworks Inc. (NASDAQ:[ZYME](https://seekingalpha.com/symbol/ZYME "Zymeworks Inc."))** have barely budged since the company obtained its first approval via an out-licensing deal for its bispecific HER2 antibody Ziihera. Global rights (ex-Asia) holder **Jazz Pharmaceuticals ([JAZZ](https://seekingalpha.com/symbol/JAZZ "Jazz Pharmaceuticals plc"))** believes

[seekalpha_articles](https://seekingalpha.com/article/4756646-zymeworks-post-approval-future)
